Imipenem-Relebactam Susceptibility in <i>Enterobacterales</i> Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)
Marta Hernández-García, María García-Castillo, Germán Bou, Emilia Cercenado, Mercedes Delgado-Valverde, Antonio Oliver, Cristina Pitart, Jesús Rodríguez‐Lozano, Nuria Tormo, José Melo‐Cristino, Margarida Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, Rui M. Ferreira, Hugo Cruz, Catarina Chaves, Joana Duarte, Leonor Pássaro, Jazmín Díaz-Regañón, Rafael Cantón
Abstract
clinical isolates recovered from difficult-to-treat infections in patients admitted to different intensive care units in Portugal and Spain. Imipenem-relebactam shows excellent activity in avoiding common resistance mechanisms in this setting, such as extended-spectrum beta-lactamases and carbapenemases widely distributed, including KPCs. We show few resistant isolates (<2%). Molecular characterization by whole-genome sequencing shows that most of the resistant isolates produced specific carbapenemase, such as OXA-48 or metalo-betalactamases. Our study updates the activity of imipenem-relebactam in light of current epidemiology in a hospital setting in which the use of this combination is needed due to the presence of infections due to multidrug-resistant isolates.